The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety run-in results from C-SOLVE (JACCRO GC-12): A randomized, non-comparative phase II trial of CapeOX or SOX plus zolbetuximab in patients with HER2-negative, CLDN18.2-positive unresectable advanced gastric or GEJ cancer.
 
Hisato Kawakami
Honoraria - Amgen; Astellas Pharma; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo; GlaxoSmithKline; Lilly Japan; Merck Serono; MSD K.K; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Abbvie; Astellas Pharma; Daiichi Sankyo Co. Ltd.,
Research Funding - Bristol Myers Squibb Foundation (Inst); Eisai (Inst); Kobayashi Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - MEDICAL & BIOLOGICAL LABORATORIES CO., LTD for Integrin avß6 autoantibody assay kit in the diagnosis of irAE enteritis
 
Satoshi Yuki
Honoraria - Astellas Pharma; Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck; Miyarisan pharmaceutical; MSD K.K; Ono Pharmaceutical; Roche; Taiho Pharmaceutical; Takeda
 
Ryohei Kawabata
No Relationships to Disclose
 
Sho Sato
No Relationships to Disclose
 
Akira Ooki
Honoraria - Astellas Pharma; Bristol Myers Squibb Foundation; Daiichi Sankyo; Ono Pharmaceutical
 
Kunihiro Tsuji
No Relationships to Disclose
 
Takeshi Kawakami
Honoraria - Astellas Pharma; Bristol-Myers Squibb Japan; Daiichi Sankyo; Lilly; Micin; MSD; Ono Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Daiichi Sankyo
 
Toshifumi Yamaguchi
Honoraria - MSD Oncology; Ono pharmaceutical., Co LTD
Consulting or Advisory Role - Daiichi Sankyo Company, Limited
 
Hisanobu Oda
No Relationships to Disclose
 
Taichi Yoshida
No Relationships to Disclose
 
Kazuaki Harada
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bristol Myers Squibb; DAIICHI SANKYO COMPANY, LIMITED; Merck Serono; MSD Oncology; Nippon Kayaku; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical
 
Yohei Kubota
Speakers' Bureau - Astellas Pharma; Bristol Myers Squibb; Merck; Taiho Pharmaceutical
 
Kyongsun Pak
Employment - Pfizer (I)
 
Yoshihiro Kakeji
Honoraria - Bristol Myers Squibb; Chugai Pharma; Covidien; DAIICHI SANKYO COMPANY, LIMITED; Johnson & Johnson; Lilly; Merck; Merck Sharp and Dohme; Miyarisan pharmaceutical; Nippon Kayaku; Olympus Marketing, Inc.; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Tsumura & Co.; Yakult Honsha
Research Funding - Taiho Pharmaceutical (Inst)
 
Masanori Terashima
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Intuitive Surgical; Johnson & Johnson; Lilly; MSD; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
 
Eishi Baba
Honoraria - Amgen; Asahi kasei pharm; Astellas Pharma; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; MSD; Novartis; Ono Pharmaceutical; Sawai Pharmaceutical Co; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Daiichi Sankyo
Research Funding - Chugai Pharma (Inst); Taiho Pharmaceutical (Inst)
 
Kei Muro
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Lilly; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Chugai Pharma; Ono Pharmaceutical
Research Funding - Amgen (Inst); Chugai Pharma (Inst); MSD (Inst); PRA Health Sciences (Inst); Taiho Pharmaceutical (Inst)
 
Yu Sunakawa
Honoraria - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Guardant Health; Incyte; Lilly Japan; Merck; MSD K.K; Ono Pharmaceutical; Sysmex; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Daiichi Sankyo; Merck; MSD K.K; Ono Pharmaceutical
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); ICON Clinical Research (Inst); IQvia (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Masashi Fujii
Travel, Accommodations, Expenses - Japan Clinical Cancer Research Organization
 
Wataru Ichikawa
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Guardant Health; Lilly; Merck; MSD K.K; Taiho Pharmaceutical